Table 1.
Comparison of the DCE and DW MR parameters among control, erlotinib, and combined erlotinib and bevacizumab (BEV) groups in HCC827.
Table 2.
Comparison of the DCE and DW MR parameters among control, erlotinib, and combined erlotinib and bevacizumab (BEV) groups in HCC827R.
Fig 1.
Plots of tumor volume among the control, erlotinib, and combined erlotinib and bevacizumab (BEV) groups in HCC827 (A) and HCC827R (B) mice before and after treatment.
Data are presented as the mean ± SD from week 0 (baseline) to week 2. *p < 0.05.
Fig 2.
MR-DCE images and parametric maps from representative mice in the HCC827 model receiving different treatment regimens.
(A) Ktrans, (B) kep and (C) iAUC90 mapping of one representative mouse from each group before and after treatment.
Fig 3.
Plots of relative changes in DCE parameters for each group in HCC827 mice.
The parameters, (A) Ktrans, (B) kep and (C) iAUC90 are shown from week 0 (baseline) to week 2.
Fig 4.
Changes of MR apparent diffusion coefficient parameter: ADC.
(A) Relative changes and (B) normalized histograms of ADC for each group in the HCC827 and HCC827R lung cancer mice.
Fig 5.
Histological staining of tumor vessels in the HCC827 and HCC827R lung cancer mice tissues.
(A) Representative slides stained with anti-CD31 antibodies for each group (200X). (B) MVD was counted in three randomly chosen 200X. Columns, mean; Bars, SD. *p < 0.05.
Fig 6.
Samples stained for cParp for each group in the HCC827 and HCC827R lung cancer mice.
(A) The brown staining of cParp images in the treatment groups of the HCC827 mice indicated the positive cells undergoing apoptosis. (B) Percentage of cParp-positive pixels. cParp, cleaved Poly (ADP-ribose) polymerase. Columns, mean; Bars, SD. *p < 0.05.